Baird Maintains Neutral on AMETEK, Raises Price Target to $280
Baird analyst Quinn Fredrickson maintains AMETEK (NYSE:AME) with a Neutral and raises the price target from $275 to $280.
Stocks · News reference
Citigroup Maintains Neutral on AMETEK, Raises Price Target to $263
Citigroup analyst Andrew Kaplowitz maintains AMETEK (NYSE:AME) with a Neutral and raises the price target from $261 to $263.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Veterinary Ophthalmology Equipment Market by Product, Animal Type, Application, End User, Region Report Forecasts Market to Reach USD 0.83 Billion by 2031, Growing at a 7.7% CAGR
The global veterinary ophthalmology equipment market is expected to grow from USD 0.57 billion in 2026 to USD 0.83 billion by 2031, at a 7.7% CAGR. Growth is driven by rising pet ownership, increased prevalence of animal eye diseases, and adoption of advanced diagnostic and surgical technologies. Treatment applications and surgical equipment segments are leading growth, with Asia Pacific emerging as the fastest-growing region.
NASA's New Moon Base Contract Could Be an Out-of-This-World Opportunity for This Under-the-Radar Nuclear Power Stock
NASA is seeking proposals for a lunar base power system, including a Stirling radioisotope generator. Ametek's subsidiary Sunpower has already developed and proven a working prototype for NASA that has operated for over 17 years, positioning the company well to win this contract and leverage the technology for future space missions.